Non alcoholic fatty liver disease and Coenzyme Q10

Effect of Coenzyme Q10 on serum levels of inflammatory markers, liver enzymes, leptin and adiponectin in patients with non alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013071313984N1

Enrollment

Registered

2013-12-18

Start date

2012-05-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcoholic Fatty liver Disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: daily consumption of 100 milligram coenzyme Q10 supplement for 3 months. Intervention 2: Control group: daily consumption of 100 milligram starch for 3 months.

Treatment - Drugs

Placebo

Intervention group: daily consumption of 100 milligram coenzyme Q10 supplement for 3 months

Control group: daily consumption of 100 milligram starch for 3 months

Eligibility

Sex/Gender

All

Age

19 Years to 59 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 19-59 years old patient with non alcoholic fatty liver disease Exclusion criteria: Patients who have diabetes, cardiovascular, kidney and other hepatic diseases; Pregnant or lactating women; Smoking; Alcohol consumption; Use of dietary supplements.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Aspartate aminotransferase. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Photometric.;Alanine aminotransferase. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Photometric.;Interlukine-6. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Hs-CRP. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Gamma-glutamyl transpeptidase. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Photometric.;TNF-a. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Adiponectin. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Leptin. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Fasting blood sugar. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Photometric.;LDL-C. Timepoint: Before intervention and 3 months after intervention. Method of measurement: undirected method with Friedewald.;Total cholestrol. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Photometric.;HDL-C. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Enzymatic.;Triglyciride. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Photometric.;VLDL. Timepoint: Before intervention and 3 months after intervention. Method of measurement: TG/5.	—

Measure

Time frame

Aspartate aminotransferase. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Photometric.;Alanine aminotransferase. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Photometric.;Interlukine-6. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Hs-CRP. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Gamma-glutamyl transpeptidase. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Photometric.;TNF-a. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Adiponectin. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Leptin. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Fasting blood sugar. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Photometric.;LDL-C. Timepoint: Before intervention and 3 months after intervention. Method of measurement: undirected method with Friedewald.;Total cholestrol. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Photometric.;HDL-C. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Enzymatic.;Triglyciride. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Photometric.;VLDL. Timepoint: Before intervention and 3 months after intervention. Method of measurement: TG/5.

—

Secondary

Measure	Time frame
Hip circumference. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Meter.;Waist circumference. Timepoint: Before intervention, 3 month after intervention. Method of measurement: Meter.;Blood pressure. Timepoint: Before intervention and 3 month after intervention. Method of measurement: Blood Pressure Monitor.;Body mass index. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Body weight in kilograms divided by height squared in meters.;Body weight. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Digital scale.	—

Measure

Time frame

Hip circumference. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Meter.;Waist circumference. Timepoint: Before intervention, 3 month after intervention. Method of measurement: Meter.;Blood pressure. Timepoint: Before intervention and 3 month after intervention. Method of measurement: Blood Pressure Monitor.;Body mass index. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Body weight in kilograms divided by height squared in meters.;Body weight. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Digital scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarnaz Farsi

School of Paramedicine, Ahvaz Jondishapur University Of Medical Sciences

farsi.f@ajums.ac.ir+98 611416236

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026